GlassScriptPhysician profile
Sabina D Dumba
NPI 1093941189
$6,118.72
in general payments reported to CMS, 2019-2025
37 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,521 · 2022: $1,623 · 2023: $988 · 2024: $703 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,145.44 | 2021-2025 | Airsupra, Breztri |
| Amgen INC. | $1,107.82 | 2021-2024 | Evenity, Otezla, Repatha |
| Abbvie INC. | $624.68 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $337.40 | 2021 | |
| Astellas Pharma US INC | $296.35 | 2021-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $292.08 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $269.69 | 2021-2022 | |
| Ardelyx, INC. | $239.18 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $178.20 | 2022-2025 | Epclusa |
| Novo Nordisk INC | $155.34 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.27 | 2021-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $138.31 | 2021-2023 | Spravato |
| Sumitomo Pharma America, INC. | $124.90 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $124.90 | 2024 | Voquezna |
| Collegium Pharmaceutical, INC. | $108.82 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $98.53 | 2022 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $73.58 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.29 | 2021-2025 | Jardiance |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Amarin Pharma, INC. | $65.73 | 2021 | |
| Lilly USA, LLC | $58.21 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Boston Scientific Corporation | $27.49 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.03 | 2024 | Austedo Xr |
| Genentech USA, INC. | $22.56 | 2021 | |
| Impel Pharmaceuticals INC. | $22.53 | 2022 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.71 | 2021 | |
| Bausch Health US, LLC | $14.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.31 | 2021 | |
| Esperion Therapeutics, INC. | $14.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabina Dumba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.